Therapeutic reflections in cholesterol homeostasis and gallstone disease: A review

Current Medicinal Chemistry

Volumn 21, Issue 12, 2014, Pages 1435-1447

  Di Ciaula, Agostino ^a   Wang, David Q H ^b   Garruti, Gabriella ^c   Wang, Helen H ^b   Grattagliano, Ignazio ^d   De Bari, Ornella ^b   Portincasa, Piero ^c  

^a Hospital of Bisceglie   (Italy)

^b SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF BARI MEDICAL SCHOOL   (Italy)

^d Pharmacovigilance Network of Italian College of General Practitioners   (Italy)

Author keywords

Cholelithiasis; Cholesterol absorption; Cholesterol synthesis; Enterohepatic circulation; Metabolic syndrome; Niemann Pick C1 like 1; Obesity

Indexed keywords

ATORVASTATIN; CHOLESTEROL; CHOLESTEROL ACYLTRANSFERASE INHIBITOR; EZETIMIBE; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEVALONIC ACID; MEVINOLIN; NIEMANN PICK C1 LIKE 1; PITAVASTATIN; PRAVASTATIN; PROTEIN; ROSUVASTATIN; SIMVASTATIN; TETRAHYDROLIPSTATIN; UNCLASSIFIED DRUG; URSODEOXYCHOLIC ACID;

BILE; CHOLELITHIASIS; CHOLESTEROL METABOLISM; CHOLESTEROL STONE; CHOLESTEROL SYNTHESIS; CRYSTALLIZATION; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; ENZYME INHIBITION; HEALTH CARE SYSTEM; HIGH RISK PATIENT; HUMAN; INTESTINE ABSORPTION; LIVER; NONHUMAN; PATHOGENESIS; REVIEW; WESTERN HEMISPHERE;

ANIMALS; CHOLESTEROL; GALLSTONES; HEPATOCYTES; HOMEOSTASIS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INTESTINES;

EID: 84899823115     PISSN: 09298673     EISSN: 1875533X     Source Type: Journal    
DOI: 10.2174/09298673113206660271     Document Type: Review

References (120)

1. Portincasa, P.; Moschetta, A.; Palasciano, G. Cholesterol gallstone disease. Lancet, 2006, 368, 230-239.
2. Wang, D.Q.; Afdhal, N.H. Genetic analysis of cholesterol gallstone formation: searching for Lith (gallstone) genes. Curr. Gastroenterol. Rep., 2004, 6, 140-150.
3. Everhart, J.E.; Khare, M.; Hill, M.; Maurer, K.R. Prevalence and ethnic differences in gallbladder disease in the United States. Gastroenterology, 1999, 117, 632-639.
4. Sandler, R.S.; Everhart, J.E.; Donowitz, M.; Adams, E.; Cronin, K.; Goodman, C.; Gemmen, E.; Shah, S.; Avdic, A.; Rubin, R. The burden of selected digestive diseases in the United States. Gastroenterology, 2002, 122, 1500-1511.
5. Action plan for liver disease research. Bethesda: NIH. Liver Disease Subcommittee of the Digestive Disease Interagency Coordinating Committee, 2004, 145-150.
6. Diehl, A.K. Epidemiology and natural history of gallstone disease. Gastroenterol. Clin. North Am., 1991, 20, 1-19.
7. Portincasa, P.; van Erpecum, K.J.; Jansen, A.; Renooij, W.; Gadellaa, M.; vanBerge-Henegouwen, G.P. Behavior of various cholesterol crystals in bile from gallstone patients. Hepatology, 1996, 23, 738-748.
8. Wang, D.Q.H.; Carey, M.C. Complete mapping of crystallization pathways during cholesterol precipitation from model bile: influence of physical-chemical variables of pathophysiologic relevance and identification of a stable liquid crystalline state in cold, dilute and hydrophilic bile salt-containing system. J. Lipid Res., 1996, 37, 606-630.
9. Attili, A.F.; Capocaccia, R.; Carulli, N.; Festi, D.; Roda, E.; Barbara, L.; Capocaccia, L.; Menotti, A.; Okolicsanyi, L.; Ricci, G.; Lalloni, L.; Mariotti, S.; Sama, C.; Scafato, E. Factors associated with gallstone disease in the MICOL experience. Multicenter Italian Study on Epidemiology of Cholelithiasis. Hepatology, 1997, 26, 809-818.
10. Attili, A.F.; Carulli, N.; Roda, E.; Barbara, B.; Capocaccia, L.; Menotti, A.; Okoliksanyi, L.; Ricci, G.; Capocaccia, R.; Festi, D.; et al. Epidemiology of gallstone disease in Italy: prevalence data of the Multicenter Italian Study on Cholelithiasis (M.I.COL.). Am. J. Epidemiol., 1995, 141, 158-165.
11. Grundy, S.M.; Barnett, J.P. Metabolic and health complications of obesity. Dis. Mon., 1990, 36, 641-731.
12. Grundy, S.M. Metabolic syndrome scientific statement by the American Heart Association and the National Heart, Lung, and Blood Institute. Arterioscler. Thromb. Vasc. Biol., 2005, 25, 2243-2244.
13. Grundy, S.M.; Cleeman, J.I.; Daniels, S.R.; Donato, K.A.; Eckel, R.H.; Franklin, B.A.; Gordon, D.J.; Krauss, R.M.; Savage, P.J.; Smith, S.C., Jr.; Spertus, J.A.; Costa, F. Diagnosis and management of the metabolic syndrome: an American Heart Association/ National Heart, Lung, and Blood Institute Scientific Statement. Circulation, 2005, 112, 2735-2752.
14. Eckel, R.H.; Grundy, S.M.; Zimmet, P.Z. The metabolic syndrome. Lancet, 2005, 365, 1415-1428.
15. Tsai, C.J.; Leitzmann, M.F.; Willett, W.C.; Giovannucci, E.L. Prospective study of abdominal adiposity and gallstone disease in US men. Am. J. Clin. Nutr., 2004, 80, 38-44.
16. Di Ciaula, A.; Wang, D.Q.; Bonfrate, L.; Portincasa, P. Current views on genetics and epigenetics of cholesterol gallstone disease. Cholesterol, 2013, 2013, 298421.
17. Wang, H.H.; Portincasa, P.; Wang, D.Q. Molecular pathophysiology and physical chemistry of cholesterol gallstones. Front. Biosci., 2008, 13, 401-423.
18. Wittenburg, H.; Lammert, F. Genetic predisposition to gallbladder stones. Semin.Liver Dis., 2007, 27, 109-121.
19. Wang, D.Q.; Zhang, L.; Wang, H.H. High cholesterol absorption efficiency and rapid biliary secretion of chylomicron remnant cholesterol enhance cholelithogenesis in gallstone-susceptible mice. Biochim. Biophys. Acta, 2005, 1733, 90-99.
20. Lammert, F.; Sauerbruch, T. Mechanisms of disease: the genetic epidemiology of gallbladder stones. Nat. Clin. Pract. Gastroenterol. Hepatol., 2005, 2, 423-433.
21. Portincasa, P.; Moschetta, A.; Puglisi, F.; Wang, D.Q.H. Medical treatment of gallstone disease. In: Borzellino, G., Cordiano, C., editors. Biliary lithiasis. Basic Science, Current Diagnosis and Management. Milano: Springer Italia S.r.l.; 2008, 149-157.
22. Lammert, F.; Miquel, J.F. Gallstone disease: from genes to evidence-based therapy. J. Hepatol., 2008, 48 Suppl 1, S124-S135.
23. Diogo, C.V.; Suski, J.M.; Lebiedzinska, M.; Karkucinska-Wieckowska, A.; Wojtala, A.; Pronicki, M.; Duszynski, J.; Pinton, P.; Portincasa, P.; Oliveira, P.J.; Wieckowski, M.R. Cardiac mitochondrial dysfunction during hyperglycemia - the role of oxidative stress and p66Shc signaling. Int. J. Biochem. Cell. Biol., 2013, 45, 114-122.
24. Wang, D.Q.H.; Neuschwander-Tetri, B.A.; Portincasa, P. The Biliary System. Colloquium Series on Integrated Systems Physiology: From Molecule to Function, 2012, 4, 1-148.
25. Wang, D.Q.; Cohen, D.E.; Carey, M.C. Biliary lipids and cholesterol gallstone disease. J.Lip.Res., 2009, 50 Suppl, S406-S411.
26. Turley, S.D.; Dietschy, J.M. The metabolism and excretion of cholesterol by the liver. In: Arias, I.M., Iakoby, W.B., Popper, H., Schachter, D., Shafritz, D.A., editors. The Liver: Biology and Pathobiology. New York: Raven Press; 1988. pp. 617-641.
27. Long, M.A.; Kaler, E.W.; Lee, S.P. Structural characterization of the micelle-vesicle transition in lecithin-bile salt solutions. Biophysical. J., 1994, 67, 1733-1742.
28. Quarfordt, S.H.; Oswald, B.; Landis, B.; Xu, H.S.; Zhang, S.H.; Maeda, N. In vivo cholesterol kinetics in apolipoprotein E-deficient and control mice. J. Lipid Res., 1995, 36, 1227-1235.
29. Robins, S.J.; Brunengraber, H. Origin of biliary cholesterol and lecithin in the rat: contribution of new synthesis and preformed hepatic stores. J. Lipid Res., 1982, 23, 604-608.
30. Schwartz, C.C.; Berman, M.; Vlahcevic, Z.R.; Halloran, L.G.; Gregory, D.H.; Swell, L. Multicompartmental analysis of cholesterol metabolism in man. Characterization of the hepatic bile acid and biliary cholesterol precursor sites. J. Clin. Invest., 1978, 61, 408-423.
31. Chapman, B.A.; Burt, M.J.; Chisholm, R.J.; Allan, R.B.; Yeo, K.H.; Ross, A.G. Dissolution of gallstones with simvastatin, an HMG CoA reductase inhibitor. Dig. Dis. Sci., 1998, 43, 349-353.
32. Erichsen, R.; Froslev, T.; Lash, T.L.; Pedersen, L.; Sorensen, H.T. Long-term statin use and the risk of gallstone disease: A population-based case-control study. Am. J. Epidemiol., 2011, 173, 162-170.
33. Hanson, D.S.; Duane, W.C. Effects of lovastatin and chenodiol on bile acid synthesis, bile lipid composition, and biliary lipid secretion in healthy human subjects. J. Lipid Res., 1994, 35, 1462-1468.
34. Smit, J.W.A.; van Erpecum, K.J.; Portincasa, P.; Renooij, W.; Erkelens, D.W.; vanBerge-Henegouwen, G.P. Effects of simvastatin and cholestyramine on bile lipid composition and gall bladder motility in patients with hypercholesterolaemia. Gut., 1995, 37, 654-659.
35. Tsai, C.J.; Leitzmann, M.F.; Willett, W.C.; Giovannucci, E.L. Statin use and the risk of cholecystectomy in women. Gastroenterology, 2009, 136, 1593-1600.
36. Lammert, F.; Wang, D.Q.; Paigen, B.; Carey, M.C. Phenotypic characterization of Lith genes that determine susceptibility to cholesterol cholelithiasis in inbred mice: integrated activities of hepatic lipid regulatory enzymes. J. Lipid Res., 1999, 40, 2080-2090.
37. Grundy, S.M.; Metzger, A.L.; Adler, R.D. Mechanisms of lithogenic bile formation in American Indian women with cholesterol gallstones. J. Clin. Invest., 1972, 51, 3026-3043.
38. Key, P.H.; Bonorris, G.G.; Marks, J.W.; Chung, A.; Schoenfield, L.J. Biliary lipid synthesis and secretion in gallstone patients before and during treatment with chenodeoxycholic acid. J. Lab. Clin.Med., 1980, 95, 816-826.
39. Salen, G.; Nicolau, G.; Shefer, S.; Mosbach, E.H. Hepatic cholesterol metabolism in patients with gallstones. Gastroenterology, 1975, 69, 676-684.
40. Nervi, F.O.; Covarrubias, C.F.; Valdivieso, V.D.; Ronco, B.O.; Solari, A.; Tocornal, J. Hepatic cholesterogenesis in Chileans with cholesterol gallstone disease. Evidence for sex differences in the regulation of hepatic cholesterol metabolism. Gastroenterology, 1981, 80, 539-545.
41. Davidson, M.H. Therapies targeting exogenous cholesterol uptake: new insights and controversies. Curr. Atheroscler. Rep., 2011, 13, 95-100.
42. Wang, D.Q. Regulation of intestinal cholesterol absorption. Annu. Rev. Physiol., 2007, 69, 221-248.
43. Wang, D.Q.; Lee, S.P. Physical chemistry of intestinal absorption of biliary cholesterol in mice. Hepatology, 2008, 48, 177-185.
44. de Bari, O.; Neuschwander-Tetri, B.A.; Liu, M.; Portincasa, P.; Wang, D.Q. Ezetimibe: its novel effects on the prevention and the treatment of cholesterol gallstones and nonalcoholic Fatty liver disease. J. Lipids, 2012, 2012, 302847.
45. Buhman, K.K.; Accad, M.; Novak, S.; Choi, R.S.; Wong, J.S.; Hamilton, R.L.; Turley, S.; Farese, R.V., Jr. Resistance to dietinduced hypercholesterolemia and gallstone formation in ACAT2- deficient mice. Nat. Med., 2000, 6, 1341-1347.
46. Wang, H.H.; Wang, D.Q. Reduced susceptibility to cholesterol gallstone formation in mice that do not produce apolipoprotein B48 in the intestine. Hepatology, 2005, 42, 894-904.
47. Amigo, L.; Quinones, V.; Mardones, P.; Zanlungo, S.; Miquel, J.F.; Nervi, F.; Rigotti, A. Impaired biliary cholesterol secretion and decreased gallstone formation in apolipoprotein E-deficient mice fed a high-cholesterol diet. Gastroenterology, 2000, 118, 772-779.
48. DenBesten, L.; Connor, W.E.; Bell, S. The effect of dietary cholesterol on the composition of human bile. Surgery, 1973, 73, 266-273.
49. Dam, H.; Prange, I.; Jensen, M.K.; Kallehauge, H.E.; Fenger, H.J. Studies on human bile. IV. Influence of ingestion of cholesterol in the form of eggs on the composition of bile in healthy subjects. Z. Ernahrungswiss., 1971, 10, 178-187.
50. Andersen, E.; Hellstrom, K. The effect of cholesterol feeding on bile acid kinetics and biliary lipids in normolipidemic and hypertriglyceridemic subjects. J. Lipid Res., 1979, 20, 1020-1027.
51. Lee, D.W.; Gilmore, C.J.; Bonorris, G.; Cohen, H.; Marks, J.W.; Cho-Sue, M.; Meiselman, M.S.; Schoenfield, L.J. Effect of dietary cholesterol on biliary lipids in patients with gallstones and normal subjects. Am. J. Clin. Nutr., 1985, 42, 414-420.
52. Istvan, E.S.; Deisenhofer, J. Structural mechanism for statin inhibition of HMG-CoA reductase. Science, 2001, 292, 1160-1164.
53. Vaughan, C.J.; Gotto, A.M., Jr.; Basson, C.T. The evolving role of statins in the management of atherosclerosis. J. Am. Coll. Cardiol., 2000, 35, 1-10.
54. Portincasa, P.; Moschetta, A.; Petruzzelli, M.; Palasciano, G.; Di Ciaula, A.; Pezzolla, A. Gallstone disease: Symptoms and diagnosis of gallbladder stones. Best Pract. Res. Clin. Gastroenterol., 2006, 20, 1017-1029.
55. Pramfalk, C.; Jiang, Z.Y.; Parini, P. Hepatic Niemann-Pick C1-like 1. Curr. Opin. Lipidol., 2011, 22, 225-230.
56. Kallien, G.; Lange, K.; Stange, E.F.; Scheibner, J. The pravastatininduced decrease of biliary cholesterol secretion is not directly related to an inhibition of cholesterol synthesis in humans. Hepatology, 1999, 30, 14-20.
57. Duane, W.C.; Hunninghake, D.B.; Freeman, M.L.; Pooler, P.A.; Schlasner, L.A.; Gebhard, R.L. Simvastatin, a competitive inhibitor of HMG-CoA reductase, lowers cholesterol saturation index of gallbladder bile. Hepatology, 1988, 8, 1147-1150.
58. Loria, P.; Bertolotti, M.; Cassinadri, M.T.; Dilengite, M.A.; Bozzoli, M.; Carubbi, F.; Concari, M.; Guicciardi, M.E.; Carulli, N. Short-term effects of simvastatin on bile acid synthesis and bile lipid secretion in human subjects. Hepatology, 1994, 19, 882-888.
59. Logan, G.M.; Duane, W.C. Lovastatin added to ursodeoxycholic acid further reduces biliary cholesterol saturation. Gastroenterology, 1990, 98, 1572-1576.
60. Krawczyk, M.; Lutjohann, D.; Schirin-Sokhan, R.; Villarroel, L.; Nervi, F.; Pimentel, F.; Lammert, F.; Miquel, J.F. Phytosterol and cholesterol precursor levels indicate increased cholesterol excretion and biosynthesis in gallstone disease. Hepatology, 2012, 55, 1507-1517.
61. Saunders, K.D.; Cates, J.A.; Abedin, M.Z.; Roslyn, J.J. Lovastatin and gallstone dissolution: a preliminary study. Surgery, 1993, 113, 28-35.
62. Smit, J.W.A.; van Erpecum, K.J.; Renooij, W.; Stolk, M.F.J.; Edgar, P.; Doornewaard, H.; vanBerge-Henegouwen, G.P. The effects of the 3-hydroxy, 3-methylglutaryl coenzyme A reductase inhibitor pravastatin on bile composition and nucleation of cholesterol crystals in cholesterol gallstone disease. Hepatology, 1995, 21, 1523-1529.
63. Tazuma, S.; Hatsushika, S.; Aihara, N.; Sagawa, H.; Yamashita, G.; Sasaki, M.; Sasaki, H.; Mizuno, S.; Tao, S.; Kajiyama, G. Inhibitory effects of pravastatin, a competitive inhibitor of hydroxymethylglutaryl coenzyme A reductase, on cholesterol gallstone formation in prairie dogs. Digestion, 1992, 51, 179-184.
64. DenBesten, L.; Safaie-Shirazi, S.; Connor, W.E.; Bell, S. Early changes in bile composition and gallstone formation induced by a high cholesterol diet in prairie dogs. Gastroenterology, 1974, 66, 1036-1045.
65. Lee, S.P.; LaMont, J.T.; Carey, M.C. Role of gallbladder mucus hypersecretion in the evolution of cholesterol gallstones. J. Clin. Invest., 1981, 67, 1712-1723.
66. Singhal, A.K.; Cohen, B.I.; Mosbach, E.H.; Une, M.; Stenger, R.J.; McSherry, C.K.; May-Donath, P.; Palaia, T. Prevention of cholesterol-induced gallstones by hyodeoxycholic acid in the prairie dog. J. Lipid Res., 1984, 25, 539-549.
67. Brenneman, D.E.; Connor, W.E.; Forker, E.L.; DenBesten, L. The formation of abnormal bile and cholesterol gallstones from dietary cholesterol in the prairie dog. J. Clin. Invest., 1972, 51, 1495-1503.
68. Saunders, K.D.; Cates, J.A.; Abedin, M.Z.; Rege, S.; Festekdjian, S.F.; Howard, W.; Roslyn, J.J. Lovastatin inhibits gallstone formation in the cholesterol-fed prairie dog. Ann. Surg., 1991, 214, 149-154.
69. Abedin, M.Z.; Narins, S.C.; Park, E.H.; Smith, P.R.; Kirkwood, K.S. Lovastatin alters biliary lipid composition and dissolves gallstones: a long-term study in prairie dogs. Digest. Dis. Sci., 2002, 47, 2192-2210.
70. Davis, K.G.; Wertin, T.M.; Schriver, J.P. The use of simvastatin for the prevention of gallstones in the lithogenic prairie dog model. Obes. Surg., 2003, 13, 865-868.
71. Smith, J.L.; Roach, P.D.; Wittenberg, L.N.; Riottot, M.; Pillay, S.P.; Nestel, P.J.; Nathanson, L.K. Effects of simvastatin on hepatic cholesterol metabolism, bile lithogenicity and bile acid hydrophobicity in patients with gallstones. J. Gastroenterol. Hepatol., 2000, 15, 871-879.
72. Hoogerbrugge-vd Linden, N.; de Rooy, F.W.M.; Jansen, H.; van Blankenstein, M. Effect of pravastatin on biliary lipid composition and bile acid synthesis in familial hypercholesterolaemia. Gut, 1990, 31, 348-350.
73. Duane, W.C. Effects of lovastatin and dietary cholesterol on bile acid kinetics and bile lipid composition in healthy male subjects. J. Lipid Res., 1994, 35, 501-509.
74. Tazuma, S.; Takizawa, I.; Kunita, T.; Mizuno, T.; Watanabe, T.; Teramen, K.; Horikawa, K.; Ochi, H.; Yamashita, Y.; Aihara, N. Effects of long-term treatment with low-dose pravastatin on biliary lipid and bile acid composition in patients with nonfamilial hyperlipoproteinemia. Metabolism, 1995, 44, 1410-1412.
75. Nitsche, R.; Schlage, J.; Ramin, V.; Kirchhoff, S.; Folsch, U.R.; Creutzfeldt, C.; Creutzfeldt, W. Influence of the HMG-CoAreductase inhibitor lovastatin on cholesterol saturation index and nucleation time of duodenal bile. Z. Gastroenterol., 1991, 29, 242-245.
76. Porsch-Ozcurumez, M.; Hardt, P.D.; Schnell-Kretschmer, H.; von, B.K.; Darui, C.; Nonhoff, J.; Abletshauser, C.; Klor, H.U. Effects of fluvastatin on biliary lipids in subjects with an elevated cholesterol saturation index. Eur. J. Clin. Pharmacol., 2001, 56, 873-879.
77. Wilson, I.R.; Hurrell, M.A.; Pattinson, N.R.; Chapman, B.A. The effect of simvastatin and bezafibrate on bile composition and gallbladder emptying in female non-insulin-dependent diabetics. J. Gastroenterol. Hepatol., 1994, 9, 447-451.
78. Miettinen, T.E.; Kiviluoto, T.; Taavitsainen, M.; Vuoristo, M.; Miettinen, T.A. Cholesterol metabolism and serum and biliary noncholesterol sterols in gallstone patients during simvastatin and ursodeoxycholic acid treatments. Hepatology, 1998, 27, 649-655.
79. Sharma, B.C.; Agarwal, D.K.; Baijal, S.S.; Saraswat, V.A. Pravastatin has no effect on bile lipid composition, nucleation time, and gallbladder motility in persons with normal levels of cholesterol. J. Clin. Gastroenterol., 1997, 25, 433-436.
80. Caroli-Bosc, F.X.; Le, G.P.; Pugliese, P.; Delabre, B.; Caroli-Bosc, C.; Demarquay, J.F.; Delmont, J.P.; Rampal, P.; Montet, J.C. Role of fibrates and HMG-CoA reductase inhibitors in gallstone formation: epidemiological study in an unselected population. Digest. Dis. Sci., 2001, 46, 540-544.
81. Gonzalez-Perez, A.; Garcia-Rodriguez, L.A. Gallbladder disease in the general population: association with cardiovascular morbidity and therapy. Pharmacoepidemiol. Drug Saf., 2007, 16, 524-531.
82. Bodmer, M.; Brauchli, Y.B.; Krahenbuhl, S.; Jick, S.S.; Meier, C.R. Statin use and risk of gallstone disease followed by cholecystectomy. JAMA, 2009, 302, 2001-2007.
83. Tazuma, S.; Kajiyama, G.; Mizuno, T.; Yamashita, G.; Miura, H.; Kajihara, T.; Hattori, Y.; Miyake, H.; Nishioka, T.; Hyogo, H.; Sunami, Y.; Yasumiba, S.; Ochi, H.; Matsumoto, T.; Abe, A.; Adachi, K.; Omata, F.; Ueno, F.; Sugata, F.; Ohguri, S.; Shibata, H.; Kokubu, S. A combination therapy with simvastatin and ursodeoxycholic acid is more effective for cholesterol gallstone dissolution than is ursodeoxycholic acid monotherapy. J. Clin. Gastroenterol., 1998, 26, 287-291.
84. Hillebrant, C.G.; Nyberg, B.; Gustafsson, U.; Sahlin, S.; Bjorkhem, I.; Rudling, M.; Einarsson, C. Effects of combined treatment with pravastatin and ursodeoxycholic acid on hepatic cholesterol metabolism. Eur. J. Clin. Invest., 2002, 32, 528-534.
85. Portincasa, P.; Wang, D.Q. Intestinal absorption, hepatic synthesis, and biliary secretion of cholesterol: where are we for cholesterol gallstone formation? Hepatology, 2012, 55, 1313-1316.
86. Davidson, M.H.; Dillon, M.A.; Gordon, B.; Jones, P.; Samuels, J.; Weiss, S.; Isaacsohn, J.; Toth, P.; Burke, S.K. Colesevelam hydrochloride (cholestagel): a new, potent bile acid sequestrant associated with a low incidence of gastrointestinal side effects. Arch. Intern. Med., 1999, 159, 1893-1900.
87. Insull, W., Jr.; Toth, P.; Mullican, W.; Hunninghake, D.; Burke, S.; Donovan, J.M.; Davidson, M.H. Effectiveness of colesevelam hydrochloride in decreasing LDL cholesterol in patients with primary hypercholesterolemia: a 24-week randomized controlled trial. Mayo Clin. Proc., 2001, 76, 971-982.
88. Hunninghake, D.; Insull, W., Jr.; Toth, P.; Davidson, D.; Donovan, J.M.; Burke, S.K. Coadministration of colesevelam hydrochloride with atorvastatin lowers LDL cholesterol additively. Atherosclerosis, 2001, 158, 407-416.
89. Portincasa, P.; Di Ciaula, A.; Baldassarre, G.; Palmieri, V.O.; Gentile, A.; Cimmino, A.; Palasciano, G. Gallbladder motor function in gallstone patients: sonographic and in vitro studies on the role of gallstones, smooth muscle function and gallbladder wall inflammation. J. Hepatol., 1994, 21, 430-440.
90. Portincasa, P.; Stolk, M.F.J.; van Erpecum, K.J.; Palasciano, G.; vanBerge-Henegouwen, G.P. Cholesterol Gallstone Formation in Man and Potential Treatments of the Gallbladder Motility Defect. Gastroenterology, 1995, 30, 63-78.
91. Portincasa, P.; Di Ciaula, A.; Vendemiale, G.; Palmieri, V.; Moschetta, A.; Vanberge-Henegouwen, G.P.; Palasciano, G. Gallbladder motility and cholesterol crystallization in bile from patients with pigment and cholesterol gallstones. Eur. J. Clin. Invest., 2000, 30, 317-324.
92. Palasciano, G.; Portincasa, P.; Belfiore, A.; Baldassarre, G.; Albano, O. Opposite effects of cholestyramine and loxiglumide on gallbladder dynamics in humans. Gastroenterology, 1992, 102, 633-639.
93. Portincasa, P.; Di Ciaula, A.; Palmieri, V.O.; Baldassarre, G.; Palasciano, G. Enhancement of gallbladder emptying in gallstone patients after oral cholestyramine. Am. J. Gastroenterol., 1994, 89, 909-914.
94. Portincasa, P.; Di Ciaula, A.; Palmieri, V.O.; vanBerge-Henegouwen, G.P.; Palasciano, G. Effects of cholestyramine on gallbladder and gastric emptying in obese and lean subjects. Eur. J. Clin. Invest., 1995, 25, 746-753.
95. Mittendorfer, B.; Ostlund, R.E., Jr.; Patterson, B.W.; Klein, S. Orlistat inhibits dietary cholesterol absorption. Obes. Res., 2001, 9, 599-604.
96. Insull, W., Jr.; Koren, M.; Davignon, J.; Sprecher, D.; Schrott, H.; Keilson, L.M.; Brown, A.S.; Dujovne, C.A.; Davidson, M.H.; McLain, R.; Heinonen, T. Efficacy and short-term safety of a new ACAT inhibitor, avasimibe, on lipids, lipoproteins, and apolipoproteins, in patients with combined hyperlipidemia. Atherosclerosis, 2001, 157, 137-144.
97. Davidson, M.H.; Maki, K.; Umporowicz, D.; Wheeler, A.; Rittershaus, C.; Ryan, U. The safety and immunogenicity of a CETP vaccine in healthy adults. Atherosclerosis, 2003, 169, 113-120.
98. Wang, H.H.; Portincasa, P.; Mendez-Sanchez, N.; Uribe, M.; Wang, D.Q. Effect of Ezetimibe on the Prevention and Dissolution of Cholesterol Gallstones. Gastroenterology, 2008, 134, 2101-2110.
99. Davis, H.R.; Veltri, E.P. Zetia: inhibition of Niemann-Pick C1 Like 1 (NPC1L1) to reduce intestinal cholesterol absorption and treat hyperlipidemia. J. Atheroscler. Thromb., 2007, 14, 99-108.
100. Rosenblum, S.B.; Huynh, T.; Afonso, A.; Davis, H.R., Jr.; Yumibe, N.; Clader, J.W.; Burnett, D.A. Discovery of 1-(4-fluorophenyl)- (3R)-[3-(4-fluorophenyl)-(3S)-hydroxypropyl]-(4S)-(4 - hydroxyphenyl)-2- azetidinone (SCH 58235): a designed, potent, orally active inhibitor of cholesterol absorption. J. Med. Chem., 1998, 41, 973-980.
101. Zuniga, S.; Molina, H.; Azocar, L.; Amigo, L.; Nervi, F.; Pimentel, F.; Jarufe, N.; Arrese, M.; Lammert, F.; Miquel, J.F. Ezetimibe prevents cholesterol gallstone formation in mice. Liver Int., 2008, 28, 935-947.
102. Wang, H.H.; Portincasa, P.; Afdhal, N.H.; Wang, D.Q. Lith genes and genetic analysis of cholesterol gallstone formation. Gastroenterol. Clin. North Am., 2010, 39, 185-207.
103. Davis, H.R., Jr.; Zhu, L.J.; Hoos, L.M.; Tetzloff, G.; Maguire, M.; Liu, J.; Yao, X.; Iyer, S.P.; Lam, M.H.; Lund, E.G.; Detmers, P.A.; Graziano, M.P.; Altmann, S.W. Niemann-Pick C1 Like 1 (NPC1L1) is the intestinal phytosterol and cholesterol transporter and a key modulator of whole-body cholesterol homeostasis. J. Biol. Chem., 2004, 279, 33586-33592.
104. Altmann, S.W.; Davis, H.R., Jr.; Zhu, L.J.; Yao, X.; Hoos, L.M.; Tetzloff, G.; Iyer, S.P.; Maguire, M.; Golovko, A.; Zeng, M.; Wang, L.; Murgolo, N.; Graziano, M.P. Niemann-Pick C1 Like 1 protein is critical for intestinal cholesterol absorption. Science, 2004, 303, 1201-1204.
105. Davies, J.P.; Scott, C.; Oishi, K.; Liapis, A.; Ioannou, Y.A. Inactivation of NPC1L1 causes multiple lipid transport defects and protects against diet-induced hypercholesterolemia. J. Biol. Chem., 2005, 280, 12710-12720.
106. Ge, L.; Wang, J.; Qi, W.; Miao, H.H.; Cao, J.; Qu, Y.X.; Li, B.L.; Song, B.L. The cholesterol absorption inhibitor ezetimibe acts by blocking the sterol-induced internalization of NPC1L1. Cell Metab., 2008, 7, 508-519.
107. Portincasa, P.; Di Ciaula, A.; Wang, H.H.; Moschetta, A.; Wang, D.Q. Medicinal treatments of cholesterol gallstones: old, current and new perspectives. Curr. Med. Chem., 2009, 16, 1531-1542.
108. Sudhop, T.; von Bergmann, K. Cholesterol absorption inhibitors for the treatment of hypercholesterolaemia. Drugs, 2002, 62, 2333-2347.
109. Sudhop, T.; Lutjohann, D.; Kodal, A.; Igel, M.; Tribble, D.L.; Shah, S.; Perevozskaya, I.; von Bergmann, K. Inhibition of intestinal cholesterol absorption by ezetimibe in humans. Circulation, 2002, 106, 1943-1948.
110. van Heek, M.; Farley, C.; Compton, D.S.; Hoos, L.; Davis, H.R. Ezetimibe selectively inhibits intestinal cholesterol absorption in rodents in the presence and absence of exocrine pancreatic function. Br. J. Pharmacol., 2001, 134, 409-417.
111. van Heek, M.; Compton, D.S.; Davis, H.R. The cholesterol absorption inhibitor, ezetimibe, decreases diet-induced hypercholesterolemia in monkeys. Eur. J. Pharmacol., 2001, 415, 79-84.
112. Davis, H.R., Jr.; Compton, D.S.; Hoos, L.; Tetzloff, G. Ezetimibe, a potent cholesterol absorption inhibitor, inhibits the development of atherosclerosis in ApoE knockout mice. Arterioscler. Thromb. Vasc. Biol., 2001, 21, 2032-2038.
113. Mathur, A.; Walker, J.J.; Al-Azzawi, H.H.; Lu, D.; Swartz-Basile, D.A.; Nakeeb, A.; Pitt, H.A. Ezetimibe ameliorates cholecystosteatosis. Surgery, 2007, 142, 228-233.
114. Tang, W.; Jia, L.; Ma, Y.; Xie, P.; Haywood, J.; Dawson, P.A.; Li, J.; Yu, L. Ezetimibe restores biliary cholesterol excretion in mice expressing Niemann-Pick C1-Like 1 only in liver. Biochim. Biophys. Acta, 2011, 1811, 549-555.
115. Valasek, M.A.; Repa, J.J.; Quan, G.; Dietschy, J.M.; Turley, S.D. Inhibiting intestinal NPC1L1 activity prevents diet-induced increase in biliary cholesterol in Golden Syrian hamsters. Am. J. Physiol. Gastrointest. Liver Physiol., 2008, 295, G813-G822.
116. Brown, J.M.; Yu, L. Opposing Gatekeepers of Apical Sterol Transport: Niemann-Pick C1-Like 1 (NPC1L1) and ATP-Binding Cassette Transporters G5 and G8 (ABCG5/ABCG8). Immunol. Endocr. Metab. Agents Med. Chem., 2009, 9, 18-29.
117. van der Velde, A.E.; Brufau, G.; Groen, A.K. Transintestinal cholesterol efflux. Curr. Opin. Lipidol., 2010, 21, 167-171.
118. Portincasa, P.; Di Ciaula, A.; Wang, H.H.; Palasciano, G.; van Erpecum, K.J.; Moschetta, A.; Wang, D.Q. Coordinate regulation of gallbladder motor function in the gut-liver axis. Hepatology, 2008, 47, 2112-2126.
119. Portincasa, P.; Di Ciaula, A.; Bonfrate, L.; Wang, D.Q. Therapy of gallstone disease: What it was, what it is, what it will be. World J. Gastrointest. Pharmacol. Ther., 2012, 3, 7-20.
120. Di Ciaula, A.; Wang, D.Q.; Portincasa, P. Gallbladder and gastric motility in obese newborns, pre-adolescents and adults. J. Gastroenterol. Hepatol., 2012, 27, 1298-1305.